# Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

> **NCT02728752** · PHASE3 · COMPLETED · sponsor: **Octapharma** · enrollment: 95 (actual)

## Conditions studied

- Dermatomyositis

## Interventions

- **DRUG:** Octagam 10%
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02728752
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-27
- **Primary completion:** 2019-11-05
- **Final completion:** 2019-11-05
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2021-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728752, "Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02728752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*